reVision Therapeutics was pleased and humbled to be chosen for the BIO-Europe 2018 Startup Slam competition. We were thrilled and more humbled to win the Audience Award for Best Pitch.
reVision is pursuing three indications, each of which could change patients’ lives.
As you might expect, repurposed and rescued products don’t have a lot of patent life left. Our dry eye candidate would have short regulatory exclusivity in the US and in the rest of the world exclusivity is uncertain. What is certain is the patients’ need for effective treatments. And so we also aspire to find a way to make a repurposed or rescued medicine with limited exclusivity more commercially attractive. How? Start with a molecule that could have high disease impact – make a drug that could sell itself. Then, get patient interest groups to contribute to the cost of development. Get payers to commit to making the drug broadly available to patients on an exclusive supply basis for a defined time. The bargain for this risk sharing? A commitment to set a price below a new molecule and above a generic, and a commitment to long term price stability.
Kari Bennet of EBD interviewed Paul about reVision, BIO-Europe, and the Startup Slam.